Novel full-range lentivirus platform from widely accessible core facility
Working with lentivirus experiences new heights with latest launches by SIRION Biotech
(PresseBox) - SIRION Biotech announced today its novel lentivirus portfolio for the most sophisticated in vitro applications. Besides its (1) non-toxic transduction enhancer coined LentiBOOST(TM) , SIRION Biotech offers (2) premade lentivirus vectors and (3) custom ser-vices. The latter allows for all possible modifications and applications ranging from complex and multiple genes expression to TET- inducible all-in-one vectors; lentivirus particles can be ordered directly or as basis for an entire cell line production. The finished cell lines come virus free and ready-to-use.
Genetic modification is a prerequisite for today's target research and cell based assay screening for compound development. Viral vectors work both in vitro and in vivo, are versatile and warrant high gene delivery rates: The viruses' own infection machinery is being used to transport genetic material into the host cells. Several viral vector platforms are in use: lentivirus lends itself to sta-ble gene modifications as opposed to transient modifications like with adenovirus (AV) and adeno-associated virus (AAV).
Specialized service providers like SIRION Biotech are able to provide custom lentivirus and the resulting stable cell pools within a matter of weeks, premade lentiviral particles can be shipped literally over night. The availability of such focused services allows for faster and more reliable research. Viral vector technologies are applicable from drug discovery to food sciences and cosmetics developments.
SIRION Biotech was founded in Munich in 2006 with the idea of enabling novel cell models clos-er to reality than ever before. This required the assembly of an all-encompassing, novel viral vector platform. Both, designing de novo viral vectors and the subsequent creation of custom cell models will pave the way for superior compound development in the life sciences. SIRION's technologies have been validated in over 300 single projects with more than 100 academic and industrial partners. As a result, cell models for drug discovery and development have become highly reliable, as have the use of new viral vectors in gene therapy and vaccine studies.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
SIRION Biotech was founded in Munich in 2006 with the idea of enabling novel cell models clos-er to reality than ever before. This required the assembly of an all-encompassing, novel viral vector platform. Both, designing de novo viral vectors and the subsequent creation of custom cell models will pave the way for superior compound development in the life sciences. SIRION's technologies have been validated in over 300 single projects with more than 100 academic and industrial partners. As a result, cell models for drug discovery and development have become highly reliable, as have the use of new viral vectors in gene therapy and vaccine studies.
Datum: 08.08.2013 - 08:00 Uhr
Sprache: Deutsch
News-ID 1252984
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Munich / New Hampshire / Tokyo
Phone:
Kategorie:
Handcrafts
Anmerkungen:
Diese Pressemitteilung wurde bisher 272 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novel full-range lentivirus platform from widely accessible core facility
"
steht unter der journalistisch-redaktionellen Verantwortung von
SIRION BIOTECH GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
